Pazopanib

Pazopanib
	File:Pazopanib structure.svg
Systematic (IUPAC) name
	5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzolsulfonamide
Clinical data
[[Regulation of therapeutic goods \|Template:Engvar data]]	US FDA: Pazopanib;
Pregnancy; category	US: D (Evidence of risk) ; ;
Routes of; administration	Oral
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Protein binding	>99%
Metabolism	Hepatic (CYP3A4, 1A2 and 2C8-mediated)
Biological half-life	31 hours (mean)
Excretion	Mostly fecal
Identifiers
CAS Number	444731-52-6
ATC code	L01XE11 (WHO)
PubChem	CID 11525740
ChemSpider	8289501
Chemical data
Formula	C21H23N7O2S
Molar mass	437.517 g/mol[[Script error: No such module "String".]]
	Script error: No such module "collapsible list".

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Pazopanib (trade name Votrient) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis. It has been approved for renal cell carcinoma by the U.S. Food and Drug Administration.^[1] Pazopanib may also be active in ovarian cancer^[2] and soft tissue sarcoma.^[3] Pazopanib also appears effective in the treatment of non-small cell lung carcinoma.^[2]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

40px	This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. v d e